AIkido Pharma Inc.

1.07-0.0200-1.83%Vol 1.90M1Y Perf 47.78%
Jun 14th, 2021 16:00 DELAYED
BID1.07 ASK1.08
Open1.10 Previous Close1.09
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap95.80M 
Earnings Rating
Price Range Ratio 52W %
29.00 
Earnings Date
5th Aug 2021

Today's Price Range

1.071.11

52W Range

0.46562.55

5 Year PE Ratio Range

-0.80005.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.93%
1 Month
18.26%
3 Months
-21.32%
6 Months
78.69%
1 Year
47.78%
3 Years
-76.90%
5 Years
-88.56%
10 Years
-99.98%

TickerPriceChg.Chg.%
AIKI1.07-0.0200-1.83
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.07-
Q02 2020--0.07-
Q01 2020--0.91-
Q03 2019--1.38-
Q02 2019--0.30-
Q01 2019--0.57-
Q01 2018--0.23-
Q02 2017--0.38-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Aug 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.90M
Shares Outstanding89.53M
Trades Count2.86K
Dollar Volume28.69M
Avg. Volume12.25M
Avg. Weekly Volume2.94M
Avg. Monthly Volume3.52M
Avg. Quarterly Volume5.44M

AIkido Pharma Inc. (NASDAQ: AIKI) stock closed at 1.07 per share at the end of the most recent trading day (a -1.83% change compared to the prior day closing price) with a volume of 1.94M shares and market capitalization of 95.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5 people. AIkido Pharma Inc. CEO is Anthony Hayes.

The one-year performance of AIkido Pharma Inc. stock is 47.78%, while year-to-date (YTD) performance is 22.5%. AIKI stock has a five-year performance of -88.56%. Its 52-week range is between 0.4656 and 2.55, which gives AIKI stock a 52-week price range ratio of 29.00%

AIkido Pharma Inc. currently has a PE ratio of -7.30, a price-to-book (PB) ratio of 0.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 9.20, a PEG ratio of 2.32, a ROA of -12.46%, a ROC of -12.71% and a ROE of -12.58%. The company’s profit margin is -%, its EBITDA margin is -92 677.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AIkido Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIkido Pharma Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for AIkido Pharma Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AIkido Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AIkido Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AIkido Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.91, ATR14 : 0.07, CCI20 : 31.23, Chaikin Money Flow : 0.14, MACD : 0.02, Money Flow Index : 61.64, ROC : 1.90, RSI : 51.51, STOCH (14,3) : 33.33, STOCH RSI : 0.33, UO : 48.29, Williams %R : -66.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AIkido Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

AIkido Pharma Inc.

AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

CEO: Anthony Hayes

Telephone: +1 703 992-9325

Address: One Rockefeller Plaza, New York 10020, NY, US

Number of employees: 5

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

75%25%

Bearish Bullish

75%25%

News

Stocktwits